Slide 1: Presentation EQL Pharma First quarter 2026/27
Presentation EQL Pharma First quarter 2026/27 1
Slide 2: Agenda
Agenda • Quarter overview • Deep dive on scrapping • The quarter excluding scrapping • Outlook • Key focus areas • Pipeline and portfolio update • Summary • Questions 2 | PRESENTATION EQL PHARMA THIRD QUARTER 2022/23
Slide 3: CEO update
CEO update • No sales growth. Revenue of 106.9 (107.2) MSEK • The gross margin was 17% (43%) – one-offs of 20 MSEK, 35% excl. one-offs • OPEX was 31.5 (25.7) MSEK Finance • EBITDA margin was -6% (24%), 12% excluding one-offs • CAPEX was 16.2 (27.2) MSEK • Growth outlook for 2026/27 is around 15% • L
Slide 4: Breakdown of the quarter
Breakdown of the quarter Scrapping • The scrapping item of 20 MSEK is mainly connected to Hospital products • The scrapping root cause is that EQL planned supply, in accordance with tender region forecast. This was done in order to gain a reputation as a reliable supplier • In some cases, mainly in
Slide 5: Breakdown of the quarter
Breakdown of the quarter The quarter excluding scrapping • Flat sales which was expected: many stockouts remained • Gross margin of 35% (excluding scrapping): This is representative for the quarter mainly due to the stockouts • EBITDA margin of 12%: Also representative, the OPEX is higher than in th
Slide 6: Outlook
Outlook • The sales outlook for the year remains around 15% • The inventory situation looks significantly better going into Q2 and Q3. Therefore, we expect a good Q2 and if the improvement works continues well, also a good Q3 • The order book for both Memprex and Mellozzan look strong through the re
Slide 7: Key drivers for 2026/27 growth
Commercial performance Key drivers for 2026/27 growth Growth components for 2026/7 Comments • Recovery in Pharmacy driven by more stable supply and new launches • Continued growth in Branded • Launch Memprex in France, Germany and Israel • Mellozzan growth in Germany and UK • De-bottlenecking and CO
Slide 8: Key drivers for 2026/27 growth and structural comeback
Commercial performance Key drivers for 2026/27 growth and structural comeback Growth components for 2026/7 Comments • Identify and resolve the root causes • Diagnosis performed • Several root causes identified • Work structured in separate workstreams to resolve • Focus on the structural problem sol
Slide 9: Behind plan on sales, but many quarters remain
Financial Goal +30% YoY & Progress (MSEK Rolling 12 Months) Behind plan on sales, but many quarters remain 9
Slide 10: Current portfolio and pipeline
Current portfolio and pipeline EQL Pharma has 49 (46) products in the market and an additional 44 (45) products in its pipeline Portfolio development Breakdown of EQL Pharma’s pipeline Expected launches per financial year 10
Slide 11: Summary
Summary • 2017 – 2025 (Q1) solid growth and growing profitability • 2025 – 2026 tougher period • Supply issues • Technically complex launches • Higher OPEX base • Every tough period has a beginning and an end, so will this one. • The goal is to emerge stronger after this tough period • After many ye